

References

Chapter 28

- 1 Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. *Journal of Pain*. 2010;**11**:1230–9.
- 2 Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *European Journal of Pain*. 2006;**10**:287–333.
- 3 IMS Health. The Use of Medicines in the United States: Review of 2010. 2011.
- 4 Therapeutic Guidelines: Analgesic Writing Group. Therapeutic Guidelines: Analgesic. In: Mashford DM, ed. *Therapeutic Guidelines: Analgesic*, 6th edn. Melbourne, Therapeutic Guidelines Ltd, 2012.
- 5 Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. *Journal of Psychiatry & Neuroscience*. 2001;**26**:30–6.
- 6 Cavagna L, Caporali R, Trifiro G, Arcoraci V, Rossi S, Montecucco C. Overuse of prescription and OTC non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. *International Journal of Immunopathology and Pharmacology*. 2013;**26**:279–81.
- 7 Boersma K, Linton SJ. Expectancy, fear and pain in the prediction of chronic pain and disability: a prospective analysis. *European Journal of Pain*. 2006;**10**:551–7.
- 8 Dix P, Sandhar B, Murdoch J, MacIntyre PA. Pain on medical wards in a district general hospital. *British Journal of Anaesthesia*. 2004;**92**:235–7.
- 9 Langley PC. The prevalence, correlates and treatment of pain in the European Union. *Current Medical Research and Opinion*. 2011;**27**:463–80.
- 10 Freemont AJ, Hoyland JA. Morphology, mechanisms and pathology of musculoskeletal ageing. *Journal of Pathology*. 2007;**211**:252–9.
- 11 Ruau D, Liu LY, Clark JD, Angst MS, Butte AJ. Sex differences in reported pain across 11 000 patients captured in electronic medical records. *Journal of Pain*. 2012;**13**:228–34.
- 12 Amandusson A, Blomqvist A. Estrogenic influences in pain processing. *Frontiers in Neuroendocrinology*. 2013;**34**:329–49.
- 13 Reid M, Engles-Horton L, Weber M, Kerns R, Rogers E, O'Connor P. Use of Opioid Medications for Chronic Noncancer Pain Syndromes in Primary Care. *Journal of General Internal Medicine*. 2002;**17**:173–9.
- 14 Radat F, Margot-Duclot A, Attal N. Psychiatric co-morbidities in patients with chronic peripheral neuropathic pain: a multicentre cohort study. *European Journal of Pain*. 2013;**17**:1547–57.
- 15 Nielsen CS, Stubhaug A, Price DD, Vassend O, Czajkowski N, Harris JR. Individual differences in pain sensitivity: genetic and environmental contributions. *Pain*. 2008;**136**:21–9.
- 16 Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Pharmacologic pain treatment in a multidisciplinary pain center do patients adhere to the prescription of the physician? *Clinical Journal of Pain*. 2010;**26**:81–6.
- 17 Dubois R, Melmed GY, Henning J, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. *Alimentary Pharmacology & Therapeutics*. 2004;**19**:197–208.
- 18 Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. *British Journal of Clinical Pharmacology*. 2001;**52**:185–92.
- 19 Barozzi N, Tett SE. Perceived barriers to paracetamol (acetaminophen) prescribing, especially follow-

- ing rofecoxib withdrawal from the market. *Clinical Rheumatology*. 2009;**28**:509–19.
- 20 Flemming K. The use of morphine to treat cancer-related pain: a synthesis of quantitative and qualitative research. *Journal of Pain and Symptom Management*. 2010;**39**:139–54.
- 21 Spitz A, Moore AA, Papaleontiou M, Granieri E, Turner BJ, Reid MC. Primary care providers' perspective on prescribing opioids to older adults with chronic non-cancer pain: a qualitative study. *BMC Geriatrics*. 2011;**11**:35.
- 22 Barreto PD, Lapeyre-Mestre M, Vellas B, Rolland Y. Potential underuse of analgesics for recognized pain in nursing home residents with dementia: a cross-sectional study. *Pain*. 2013;**154**:2427–31.
- 23 United Nations Office on Drugs and Crime. The Non-Medical Use of Prescription Drugs. Policy Direction Issues. Vienna, United Nations, 2011: 1–96.
- 24 Weston AL, Weinstein AM, Barton C, Yaffe K. Potentially inappropriate medication use in older adults with mild cognitive impairment. *Journals of Gerontology A Biological Sciences and Medical Sciences*. 2010;**65**:318–21.
- 25 McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. *Journal of Psychiatric Research*. 2011;**45**:1027–35.
- 26 Allen JP, Chango J, Szwedo D, Schad M, Marston E. Predictors of susceptibility to peer influence regarding substance use in adolescence. *Child Development*. 2012;**83**:337–50.
- 27 Volkow ND. *Prescription Drugs: Abuse and Addiction*. Bethesda, MD, National Institute on Drug Abuse, 2011.
- 28 *Australian Medicines Handbook*. Adelaide, Australian Medicines Handbook Pty Ltd, 2014.
- 29 Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. *Pharmacoepidemiology & Drug Safety*. 2011;**20**:177–84.
- 30 O'Brien A. Starting clozapine in the community: a UK perspective. *CNS Drugs*. 2004;**18**:845–52.
- 31 Woods D. *New Zealand Formulary*. Dunedin, New Zealand Formulary, 2014.
- 32 Ronsley R, Scott D, Warburton WP, Hamdi RD, Louie DC, Davidson J, Panagiotopoulos C. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. *Canadian Journal of Psychiatry*. 2013;**58**:361–9.
- 33 Alessi-Severini S, Dahl M, Schultz J, Metge C, Raymond C. Prescribing of psychotropic medications to the elderly population of a Canadian province: a retrospective study using administrative databases. *PeerJ*. 2013;**1**:e168.
- 34 Brunton LL, Lazo JS, Parker KL. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. New York, McGrawHill, 2006.
- 35 Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. *Journal of Clinical Psychiatry*. 2002;**63**:892–909.
- 36 Birnbaum M, Sharif Z. Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. *Patient Preference and Adherence*. 2008;**2**:233–40.
- 37 Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. *Journal of Medical Economics*. 2013;**16**:231–9.
- 38 Kishimoto T, Robenzadeh A, Leucht C, Watanake K, Mimura M, Borenstein M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. *Schizophrenia Bulletin*. 2014;**40**:192–213.
- 39 Byerly MJ, Nakonezny PA, Lescouffair E. Antipsychotic medication adherence in schizophrenia. *Psychiatric Clinics of North America*. 2007;**30**:437–52.
- 40 Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. *Australian and New Zealand Journal of Psychiatry*. 2013;**47**:74–87.
- 41 British Medical Association and Royal Pharmaceutical Society of Great Britain. *British National Formulary*. London, British Medical Association, 2013.
- 42 van der Hoof CS, Jong GW, Dieleman JP, Verhamme KM, van der Cammen TJ, Stricker BH, Sutrenboom MC. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria – a population-based cohort study. *British Journal of Clinical Pharmacology*. 2005;**60**:137–44.

- 43 McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Medicine*. 2004;**2**:13.
- 44 Banerjee I, Roy B, Sathian B, Banerjee I, Chakraborty PK, Saha A. Socio demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from western region of Nepal. *BMC Psychiatry*. 2013;**13**:96.
- 45 Hollingworth SA, Siskind DJ, Nissen LM, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia 2002–2007. *Australian and New Zealand Journal of Psychiatry*. 2010;**44**:372–7.
- 46 Meng X, D’Arcy C, Tempier R. Trends in psychotropic use in Saskatchewan from 1983 to 2007. *Canadian Journal of Psychiatry*. 2013;**58**:426–31.
- 47 Toh S, Li Q, Cheetham TC, Cooper W, Davis R, Dublin S, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the US, 2001–2007: a population-based study of 585 615 deliveries. *Archives of Women’s Mental Health*. 2013;**16**:149–57.
- 48 Ng CG, Boks MP, Smeets HM, Zainal NZ, de Wit NJ. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. *Psycho-oncology*. 2013;**22**:762–7.
- 49 Gorevski E, Bian B, Kelton CM, Boone JEM, Guo JJ. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991–2009. *Annals of Pharmacotherapy*. 2012;**46**:503–12.
- 50 Lasserre A, Younès N, Blanchon T, Cantegreil-Kallen I, Passerieux C, Thomas G, et al. Psychotropic drug use among older people in general practice: discrepancies between opinion and practice. *British Journal of General Practice*. 2010;**60**:e156–62.
- 51 Smith A, Sketris I, Cooke C, Gardner D, Kisely S, Tett S. A comparison of benzodiazepines and related drug use in Nova Scotia, Canada and Australia. *Canadian Journal of Psychiatry*. 2008;**53**:545–52.
- 52 Smith A, Tett S. How do different age groups use benzodiazepines and antidepressants? Analysis of an Australian administrative database, 2003–6. *Drugs and Aging*. 2009;**26**:113–22.
- 53 Alessi-Severini S, Bolton JM, Enns MW, Dahl M, Collins DM, Chateau D, Sareen J. Use of benzodiazepines and related drugs in Manitoba: a population-based study. *Canadian Medical Association Open Access Journal*. 2014;**2**:E208–16.
- 54 Linjakumpu T, Hartikainen S, Klaukka T, Koponen H, Kivela SL, Isoaho R. Psychotropics among the home-dwelling elderly – increasing trends. *International Journal of Geriatric Psychiatry*. 2002;**17**:874–83.
- 55 Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. *Canadian Medical Association Open Access Journal*. 2014;**2**:E225–32.
- 56 McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiologic Reviews*. 2008;**30**:67–76.
- 57 Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. *Archives of Internal Medicine*. 2010;**170**:89–95.
- 58 Gustafsson M, Karlsson S, Lovheim H. Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. *BMC Pharmacology and Toxicology*. 2013;**14**:10.
- 59 Seida JC, Schouten JR, Mousavi SS, Hamm M, Beath A, Vandermeer B, et al. First- and second-generation antipsychotics for children and young adults. *Comparative Effectiveness Reviews*. 2012;**39**:11(12)-EHC077-EF.
- 60 Smith A, Tett S. Improving the use of benzodiazepines – Is it possible? A non-systematic review of interventions tried in the last 20 years. *BMC Health Services Research*. 2010;**10**:321.
- 61 Azermai M, Elseviers M, Petrovic M, Van Bortel L, Vander Stichele R. Geriatric drug utilisation of psychotropics in Belgian nursing homes. *Human Psychopharmacology*. 2011;**26**:12–20.
- 62 Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. *CNS Drugs*. 2003;**17**:825–37.
- 63 Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. *Pharmacoepidemiology and Drug Safety*. 2010;**19**:280–8.
- 64 Siriwardena AN, Qureshi MZ, Dyas JV, Middleton H, Orner R. Magic bullets for insomnia? Patients’ use and experiences of newer (Z drugs) versus older

- (benzodiazepine) hypnotics for sleep problems in primary care. *British Journal of General Practice*. 2008;**58**:417–22.
- 65 Williams JJW, Mulrow CD, Chiquette E, Noël PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary: clinical guideline, Part 2. *Annals of Internal Medicine*. 2000;**132**:743–56.
- 66 Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. *Journal of Affective Disorders*. 2000;**58**:19–36.
- 67 Connor DF, In R. Stimulants. In: Barkley RA, ed. *Attention Deficit/Hyperactivity Disorder: A Handbook for Diagnosis and Treatment*, 3rd edn. New York, Guilford Press, 2005: 608–47.
- 68 Moriyama TS, Polanczyk GV, Terzi FS, Faria KM, Rohde LA. Psychopharmacology and psychotherapy for the treatment of adults with ADHD – a systematic review of available meta-analyses. *CNS Spectrums*. 2013:1–11.
- 69 Solomon CG, Volkow ND, Swanson JM. Adult attention deficit–hyperactivity disorder. *New England Journal of Medicine*. 2013;**369**:1935–44.
- 70 Shaw M, Hodgkins P, Caci H, Yougn S, Kahle J, Woods AG, Arnold LE. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. *BMC Medicine*. 2012;**10**:99.
- 71 Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. *European Child & Adolescent Psychiatry*. 2006;**15**:476–95.
- 72 Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. *Neuropsychiatric Disease and Treatment*. 2009;**5**:215.
- 73 Safer DJ, Zito JM. Concomitant psychotropic medication for youths. *American Journal of Psychiatry*. 2003;**160**:438–49.
- 74 Ahmed R, Aslani P. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2013;**13**:791–815.
- 75 Olfson M, Marcus SC, Zhang HF, Wan GJ. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. *Journal of Managed Care Pharmacy*. 2007;**13**:570.
- 76 Bokhari FA, Heiland F, Levine P, Ray GT. Risk factors for discontinuing drug therapy among children with ADHD. *Health Services and Outcomes Research Methodology*. 2008;**8**:134–58.
- 77 Geirs DP, Pottegård A, Halldórsson M, Zoëga H. A nationwide study of ADHD drug use among adults in Iceland 2003–2012. *Basic & Clinical Pharmacology & Toxicology*. 2014;**115**(5):417–22.
- 78 Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. *Pediatrics*. 1990;**86**:184–92.
- 79 Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, et al. Sudden death and use of stimulant medications in youths. *American Journal of Psychiatry*. 2009;**166**:992–1001.
- 80 Nissen SE. ADHD drugs and cardiovascular risk. *New England Journal of Medicine*. 2006;**354**:1445–8.
- 81 Cooper WO, Habel LA, Sox CM, Chan, KA, Arbogast PG, Cheetham C, et al. ADHD drugs and serious cardiovascular events in children and young adults. *New England Journal of Medicine*. 2011;**365**:1896–904.
- 82 Mathers CD, Fat DM, Boerma J. *The Global Burden of Disease: 2004 Update*. Geneva, World Health Organization, 2008.
- 83 Lee AM, Lam SK, Lau SMSM, Chong CSY, Chui HW, Fong DYT. Prevalence, course, and risk factors for antenatal anxiety and depression. *Obstetrics & Gynecology*. 2007;**110**:1102–12.
- 84 Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, et al. One-month prevalence of mental disorders in the United States: based on five Epidemiologic Catchment Area sites. *Archives of General Psychiatry*. 1988;**45**:977.
- 85 Rodda J, Walker Z, Carter J. Depression in older adults. *British Medical Journal*. 2011;**343**:d5219.
- 86 Bryant C, Jackson H, Ames D. The prevalence of anxiety in older adults: methodological issues and a review of the literature. *Journal of Affective Disorders*. 2008;**109**:233–50.
- 87 Polanczyk G, de Lima M, Horta B, Biederman J, Rohde L. The worldwide prevalence of ADHD: a

- systematic review and metaregression analysis. *American Journal of Psychiatry*. 2007;**164**:942–8.
- 88** Simon V, Czobor P, Bálint S, Mészáros Á, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. *British Journal of Psychiatry*. 2009;**194**:204–11.
- 89** Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. *Journal of the American Academy of Child & Adolescent Psychiatry*. 2014;**53**:34–46, e2.
- 90** Zoega H, Furu K, Halldorsson M, Thomsen PH, Sourander A, Martikainen J. Use of ADHD drugs in the Nordic countries: a population-based comparison study. *Acta Psychiatrica Scandinavica*. 2011;**123**:360–7.
- 91** Zoëga H, Valdimarsdóttir UA, Hernández-Díaz S. Age, academic performance, and stimulant prescribing for ADHD: a nationwide cohort study. *Pediatrics*. 2012;**130**:1012–18.
- 92** Cox ER, Motheral BR, Henderson RR, Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. *Pediatrics*. 2003;**111**:237–43.
- 93** Helgason T, Tómasson H, Zoega T. Antidepressants and public health in Iceland Time series analysis of national data. *British Journal of Psychiatry*. 2004;**184**:157–62.
- 94** IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2011. Available from: http://www.environmentalhealthnews.org/ehs/news/2013/pdf-links/IHII_Medicines_in_U.S_Report_2011-1.pdf (last accessed 18 November 2015).
- 95** Mojtabei R, Olsson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. *Health Affairs*. 2011;**30**:1434–42.
- 96** Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. *Lancet*. 2003;**361**:653–61.
- 97** Vitiello B, Swedo S. Antidepressant medications in children. *New England Journal of Medicine*. 2004;**350**:1489–91.
- 98** Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. *Journal of the American Medical Association*. 2007;**297**:1683–96.
- 99** Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. *American Journal of Psychiatry*. 2006;**163**:41–7.
- 100** Pottegård A, Zoëga H, Hallas J, Damkier P. Use of SSRIs among Danish children: a nationwide study. *European Child & Adolescent Psychiatry*. 2014;**23**(12):1211–18.
- 101** Zuvekas SH, Vitiello B. Stimulant medication use among US children: a twelve-year perspective. *American Journal of Psychiatry*. 2012;**169**:160.
- 102** McCarthy S, Wilton L, Murray M, Hodgkins P, Asherson P, Wong I. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. *BMC Pediatrics*. 2012;**12**:78.
- 103** Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. *Health Affairs (Project Hope)*. 2007;**26**:450–7.
- 104** Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. *Journal of the American Medical Association Psychiatry*. 2013;**70**(7):740–9.
- 105** Lichtenstein P, Halldner L, Zetterqvist J, Sjölander A, Serlachius E, Fazel S, et al. Medication for attention deficit–hyperactivity disorder and criminality. *New England Journal of Medicine*. 2012;**367**:2006–14.
- 106** Chang Z, Lichtenstein P, D’Onofrio BM, Sjölander A, Larsson H. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. *Journal of the American Medical Association Psychiatry*. 2014;**71**(3):319–25.
- 107** Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. *Pediatrics*. 2009;**124**:875–80.
- 108** World Health Organization. Mental Health Action Plan 2013. Available from: http://www.who.int/mental_health/publications/action_plan/en/ (last accessed 18 November 2015).